Morepen Laboratories Limited · NSE:MOREPENLAB
Morepen Laboratories — Q2 FY2019 Earnings Presentation
12 slides from Morepen Laboratories's earnings presentation, Nov 1, 2018
Slide 1: Cover letter to NSE and BSE
Date: 01/11/2018 To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, Bandra Kurla Complex, Floor 25, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai- 400 051 Dalal Street, Mumbai- 400 001 Tel No: (022) 26598100 - 8114 Phones: 91-22-22721233/4 Fax No: (022) 26598120 Fax: 91-22-2272
Slide 2: Investors Presentation (Q2) September 2018
“ I CHOOSE INVESTORS PRESENTATION (Q2) SEPTEMBER 2018
Slide 3: Disclaimer
Disclaimer: This presentation has been prepared by Morepen Laboratories Limited (“Company”) solely for information purposes without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation contains expressed or implied forward looking
Slide 4: Synopsis of Q2'FY19 Performance
Synopsis of Q2’FY19 Performance ₹ crores Consolidated Consolidated Y-o-Y Q2’FY19 Q2’FY18 Growth Net Revenue 173.93 150.54 15.5% Expenditure 159.03 130.42 20.4% EBIDTA 16.90 20.12 (16.%) Interest 0.32 1.31 (75.9%) Cash Surplus 16.58 18.81 (11.9%) Dep. & Amortization 9.79 7.73 26.7% Income Tax (0.19)
Slide 5: Highlights of Q2'FY19 Performance
Highlights of Q2’FY19 Performance ₹ crores • Net Revenue up by 15% at Rs. 173.93 crore backed by improved sales revenue from Home Diagnostics and Formulations. Export sales up by 38 % at Rs. 65.05 crore • Loratadine records remarkable growth amongst bulk drugs in the quarter @29%: 31% growth in the
Slide 6: Segments wise growth
Segments wise growth ₹ crores • Overall business for the Quarter (Q2’FY19) has grown at 15% as compared to Q2’FY18 174 • API Export has shown extremely good results having grown at 38% for the 15% Q2’FY19. Total API business contributed 52% to the quarterly sales. 151 • Home Diagnostic Devices busin
Slide 7: API: Increasing Export Business
API: Increasing Export Business ₹ crores • API Export has got a jump of 38% during the Q2’FY19 as compared to Q2’FY18 API Sales while total API business has grown by 4% 89.5 • Loratadine sales has grown by 29% in Q2’FY19 on Y-to-Y basis. Export of Loratadine has gone up by 31% this quarter Q2’FY19 8
Slide 8: Growing Branded Portfolio
Growing Branded Portfolio: ₹ crores • Dr. Morepen brand basket has grown from Rs.62.58 crores to Rs. 83.35 crores for the Q2’FY19 and has registered an upside of 33% as compared Q2’FY18 • Within the basket, Diagnostic Devices business has shown has registered a growth of 25% while Finished Dosages h
Slide 9: Devices Business - Growth Driver
Devices Business - Growth Driver ₹ crores • Home Devices portfolio has been growing with fast pace and has recorded a growth of 25% during the quarter. 35.0 • Blood Glucose Monitors have marked a growth of 38% in Q2’FY19 as against 25% Q2’FY18. Total Gluco monitors installed during Q2’FY19 were 16%
Slide 10: Finished Dosages: Healthy upside
Finished Dosages: Healthy upside ₹ crores • Finished Dosages has bounced back strongly with a increase of 57% in Q2FY’19 as 35.26 compared to last year same quarter. • Branded Prescription (Rx) products has grown by 24% during the Q2’FY’19 57% • Good growth is seen in Gastrointestinal (20%) products
Slide 11: Strong OTC Business
Strong OTC Business: ₹ crores • Total OTC category has registered a growth of 7.35% during the quarter. 13.08 • Burnol Sales have gone up strongly by 10% during the Q2’FY19 on Y-to-Y basis 7% • Other small brands which are distribution and reach based have also got a substantial gain of 22% in the s
Slide 12: Thank You
Tran You a MOREPEN The Joy Of Growing Together
Morepen Laboratories — Q2 FY2019 Earnings Presentation on 6ix